CFM
FULC icon

Catalyst Funds Management’s Fulcrum Therapeutics FULC Stock Holding History

Catalyst Funds Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,594
Closed -$24.5K – 1315
2024
Q1 		$24.5K Buy
+2,594
New +$23.2K 0.01% 717

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Catalyst Funds Management's FULC Position: Q2 2024 in Review

Catalyst Funds Management sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 2,594 shares — an estimated $24.5K sold.

Catalyst Funds Management first reported a position in FULC in Q1 2024 and held it in 1 quarter. The position peaked at $24.5K in Q1 2024. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Catalyst Funds Management reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 2,594 Fulcrum Therapeutics shares in Q2 2024, an estimated $24.5K.
  • Catalyst Funds Management first reported a position in Fulcrum Therapeutics in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Fulcrum Therapeutics position peaked at $24.5K in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.